Press Releases

11/9/23

Arch Therapeutics Provides Year End Operational Update

11/2/23

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

09/13/23

Arch Therapeutics Provides AC5® Commercialization Update

09/7/23

Arch Therapeutics Completes Financing as Bridge to Uplisting

04/25/23

Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

04/5/23

Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect

03/9/23

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

03/7/23

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

01/18/23

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

01/17/23

Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

12/5/22

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

10/18/22

Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

10/11/22

Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall

09/23/22

Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

09/20/22

Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

09/16/22

Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

09/7/22

Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System

09/1/22

Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System

07/7/22

Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

06/22/22

Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

05/9/22

Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

04/13/22

Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

04/4/22

Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

03/14/22

Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

01/6/22

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

01/4/22

Arch Therapeutics Announces Appointment of Guy Fish to the Board

12/13/21

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System

12/1/21

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

11/1/21

Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC)

10/25/21

Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall

10/18/21

Arch Therapeutics Launches Experts in Wound Care Program

10/13/21

Arch Therapeutics Provides Corporate Update

10/6/21

Arch Therapeutics to Present at the LD Micro Main Event

10/4/21

Arch Therapeutics Launches Coverage and Reimbursement Pilot

09/30/21

Arch Therapeutics Announces Appointment of Larry Hicks to the Board

09/2/21

Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities

07/12/21

Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

07/7/21

Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

06/2/21

Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

05/10/21

Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)

05/3/21

Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer

04/27/21

Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC)

04/19/21

Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results

03/2/21

Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021

02/18/21

Arch Therapeutics Announces Closing of $6.9 Million Private Placement

02/12/21

Arch Therapeutics Announces $6.9 Million Private Placement

01/5/21

Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021

01/4/21

Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.

12/11/20

Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference

11/10/20

Arch Raises Approximately $1.1 Million with Convertible Note Issuance

11/9/20

Arch Therapeutics’ AC5 Advanced Wound System Presented at the 2020 Symposium on Advanced Wound Care (SAWC) Fall

10/22/20

Arch Therapeutics, Inc. to Present at the Virtual Investor KOL Roundtable

10/14/20

Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC) Fall

09/10/20

Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET

08/26/20

Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET

08/11/20

Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting

08/7/20

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020

06/8/20

Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series

06/5/20

Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice

06/3/20

Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit

04/13/20

Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe

03/23/20

Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain

03/18/20

Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th

03/4/20

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020

03/2/20

Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference

01/8/20

Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020

10/17/19

Arch Therapeutics Announces $2.5 Million Registered Direct Offering

10/7/19

Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY

09/3/19

Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference

08/5/19

Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat

05/30/19

Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational

05/13/19

Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

04/24/19

Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video

03/11/19

Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

02/5/19

Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

12/20/18

Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019

12/17/18

Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

12/6/18

Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

12/4/18

Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

11/28/18

Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe

11/26/18

Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

10/1/18

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

09/25/18

Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

09/5/18

Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5

08/28/18

Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018

08/16/18

Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018

07/20/18

Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

06/29/18

Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering

06/26/18

Arch Therapeutics Provides Skin Sensitization Study Status Update

06/15/18

Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

05/15/18

Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018

05/8/18

Arch Therapeutics Provides Update on Study Initiation and 510(k)

03/12/18

Arch Therapeutics Provides Update on 510(k)

03/5/18

Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018

02/5/18

Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application

01/2/18

Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018

12/18/17

Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA

11/28/17

Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017

09/20/17

Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences

09/12/17

Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity

09/6/17

Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

07/25/17

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel

06/6/17

Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

05/22/17

Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

03/6/17

Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017

02/27/17

Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference

02/21/17

Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering

02/16/17

Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)

02/8/17

Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017

02/2/17

Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics

01/23/17

Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference

01/5/17

Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017

12/5/16

Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016

10/31/16

Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study

10/11/16

Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016

09/15/16

Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016

09/12/16

Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference

08/22/16

Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016

08/19/16

Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire

08/15/16

Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study

06/6/16

Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5

05/27/16

Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement

05/16/16

Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics

05/10/16

Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides

04/26/16

Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016

04/25/16

Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides

04/11/16

Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides

04/5/16

Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides

03/22/16

Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans

03/14/16

Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark

03/10/16

Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016

03/9/16

Arch Therapeutics Receives ISO 13485 Certification for AC5

03/7/16

Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment

02/17/16

Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016

02/8/16

Arch Therapeutics to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016

02/3/16

Arch Therapeutics to Present at the BIO CEO & Investor Conference on Monday, February 8, 2016

01/4/16

Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016